

GENERAL INFORMATION

MEETING VENUE

Hotel Splendid

Via Sempione, 12 - 28831 Baveno (VB)

T: 0039 0323 92 45 83

ORGANIZING SECRETARIAT



Start Promotion S.r.l.

Via Mauro Macchi, 50 - 20124 Milano

T: 0039 02 67 07 13 83 | F: 0039 02 67 07 2294

www.startpromotion.it | info@startpromotion.it

ACCREDITAMENTO ECM

La Commissione Nazionale per la Formazione Continua ha espresso il proprio parere positivo all'accREDITamento standard di Start Promotion S.r.l. (numero assegnato 622). Questo Convegno darà diritto a **n. 8 Crediti ECM** per l'anno 2014. Il Convegno è accreditato per la professione di **"Medico Chirurgo"** (Discipline di riferimento: **Gastroenterologia/Epatologia, Malattie Infettive, Chirurgia Generale, Medicina Interna, Microbiologia e Virologia**). Per la certificazione ECM è assolutamente indispensabile compilare in ogni sua parte (in particolare nome e cognome, data e luogo di nascita, codice fiscale, indirizzo e-mail, e numero di iscrizione all'Ordine/Collegio Professionale) il Modulo Dati ECM, la scheda di valutazione ed il questionario di apprendimento. Durante il Convegno i partecipanti dovranno registrare la propria presenza in aula ad inizio e fine lavori. Attenzione: Per conseguire i crediti formativi sarà necessario garantire la propria presenza al 100% del tempo totale, rispondere correttamente al 75% delle domande contenute nel questionario di valutazione di apprendimento e compilare tutta la modulistica e riconsegnarla al termine del Convegno alla postazione ECM presso la segreteria.

Con il contributo educativo di | With an educational grant of:



5th Expert Meeting on the Management of PATIENTS WITH HCV INFECTION



Baveno, Italy | September 17/18 2014

SCIENTIFIC RATIONALE

The hepatitis C virus represents, and is expected to represent in the near future, one of the major causes of chronic liver disease in our country, also due to the current immigration flows. In this rapidly changing field, more and more expensive drugs offer interesting treatment perspectives. It is, therefore, urgent to share the methods for selecting the subset of patients to be treated with priority using safer but expensive molecules.

On-label and off-label combination of drugs should be discussed in order

to improve the choice of treatment schedules. Not least, the currently available first generation PIs might be still utilized, based on recent results which, using new futility rules, showed high efficacy with low risks and costs.

The Meeting is targeted to specialists in Internal Medicine, Hepatology, Gastroenterology, and Infectious Diseases, aiming to provide them with the opportunity to interact with the Experts and discuss all the clinical issues of chronic hepatitis C and its complications.

PROGRAM DIRECTOR AND SCIENTIFIC COORDINATOR

Savino Bruno

Contract Professor of Internal Medicine, University of Milan Bicocca
Head of Internal Medicine and Liver Unit
A.O. Fatebenefratelli e Oftalmico, Milano

FACULTY

Alessio Aghemo

Unità Operativa di Gastroenterologia I, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano

Tarik Asselah

Hepatology Department, University Paris Diderot 7 Beaujon Hospital, Clichy, France

Marc Bourliere

Hepato-Gastroenterology Department, Saint Joseph Hospital, Marseilles, France

Raffaele Bruno

Struttura Complessa di Malattie Infettive e Tropicali, IRCCS Policlinico S. Matteo, Pavia

Savino Bruno

Struttura Complessa di Medicina Interna ed Epatologia Azienda Ospedaliera Fatebenefratelli e Oftalmico, Milano

Carlo Cammà

Unità Operativa di Gastroenterologia, AOU Policlinico "Paolo Giaccone", Palermo

Alessia Ciancio

Dipartimento di Scienze Mediche - SCDU Gastroenterologia ed Epatologia, AOU San Giovanni Battista Molinette, Torino

Antonio Craxi

Unità Operativa di Gastroenterologia, AOU Policlinico "Paolo Giaccone", Palermo

Geoffrey Dusheiko

Royal Free Hospital and University College School of Medicine, London, UK

Vlad Ratziu

Hepatology, Pitié Salpêtrière Hospital, Pierre et Marie Curie University, Paris, France

Didier Samuel

Hepatology and Gastroenterology, Paris-Sud University, Villejuif, France

Gloria Taliani

Dipartimento di Malattie Infettive e Tropicali, Università degli Studi "La Sapienza", Roma

SCIENTIFIC PROGRAM - SEPTEMBER 17, 2014

12.00 - 12.30	Registration
12.30 - 14.30	Welcome Lunch
14.30 - 14.45	Course presentation S. BRUNO
14.45 - 15.15	Lecture: Will NASH be the future HCV? V. RATZIU
15.15 - 15.30	Coffee Break
15.30 - 18.45	Workshops: Red, Green, Blue, Brown, Black

GROUPS

RED

Special populations: are they changed with the new DAAs?
TUTOR: R. BRUNO

GREEN

Cost-benefit evaluation: first-generation vs second-generation DAAs
TUTOR: C. CAMMÀ

BLUE

The future of IFN-based therapy with the first and second-generation DAAs
TUTOR: A. CIANCIO

BROWN

Patients with advanced fibrosis and cirrhosis. New futility rules with the first-generation DAAs
TUTOR: S. BRUNO

BLACK

A review of the 2014 international AASLD vs EASL guidelines
TUTOR: A. AGHEMO

SCIENTIFIC PROGRAM - SEPTEMBER 18, 2014

08.30 - 09.00	Lecture: How can we fill the time-gap until the availability of all-oral combination? S. BRUNO
09.00 - 09.30	Lecture: On and off label all-oral. Light and shadow in cirrhotics T. ASSELAH
09.30 - 10.00	Lecture: What's the better DAAs combination for patients who failed to triple therapy with first generation PIs M. BOURLIERE
10.00 - 10.30	Lecture: Will there be a future for liver transplant without HCV? D. SAMUEL
10.30 - 11.00	Coffee Break
11.00 - 11.30	Lecture: Overview of new treatments: will new molecules be used as a vaccine? G. DUSHEIKO
11.30 - 12.00	Lecture: Overview of new treatments: target population with severe illness or widespread use by the primary care? A. CRAXI
12.00 - 13.00	Workshop results: Groups Red and Blue CHAIRPERSON: G. TALIANI
13.00 - 14.00	Lunch
14.00 - 15.30	Workshop results: Groups Brown, Black and Green CHAIRPERSON: G. TALIANI
15.30 - 16.00	Discussion and conclusion